NASDAQ · PTIXW
Protagenic Therapeutics, Inc.
$0.00 $0.00 (+0.00%) 1DKey Metrics
$8.67K
Market cap
—
P/E · TTM
$0
Revenue · TTM
−$5.16M
Net income
EPS · TTM
$-2.08
Dividend yield
—
Free cash flow
—
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap—
Enterprise value—
Shares outstanding—
52-wk range$0.00 – $0.30
Avg volume · 20D25.3K
Net cash
—
Book value / share$-0.97
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Protagenic Therapeutics, Inc.
IPO dateApr 27, 2021
Employees5
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
-808.6% · —
Financial Health
Current ratio0.34
Quick ratio0.34
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital−$4.52M
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
1 / 9
Weak fundamentals · 1 of 9 signals passing
Altman Z-Score
-7.9
Distress zone (< 1.81) · elevated risk
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings